[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
ZHU Huijuan, REN Jingtian.
Safety Risks of Human Rabies Immunoglobulin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
|
[3] |
LI Dong, ZHAO Yan.
Roles of National Arthroplasty Registries in Post-Market Surveillance of Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 640-644.
|
[4] |
CHEN Huan, LIANG Jun, ZHAO Wei, XIA Qingrong.
Clinical Features and Risk Factors of Liver Injury Induced by Atypical Antipsychotic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 410-414.
|
[5] |
LAN Xiaoqian, GUO Wei.
Trough Steady-State Concentration/Dose Ratio and Contributors to Adverse Drug Reactions of Sulpiride
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 420-423.
|
[6] |
WANG Shuan, HUANG Can, QI Lamei.
Establishment and Evaluation of Apatinib-Induced Hypertension Prediction Model Based on Real-World Data
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 429-435.
|
[7] |
LONG Minjuan, ZHAO Xu, GUO Longxin, CAI Yuhan, LIN Li, ZHU Shengkai, LIU Wenlong, SONG Haibo, XIAO Xiaohe.
Big Data Analysis of Liver Adverse Reactions Monitoring of Chinese and Western Medicines Based on Age Correction and Risk Warning for Dermatologic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 271-275.
|
[8] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[9] |
GUO Yuansheng, ZUO Tiantian, LIU Li'na, WEI Feng, DONG Zhe, LI Jing, JIN Hongyu, MA Shuangcheng.
Twenty-eight elements in Coicis Semen and risk assessment by stir-frying with bran by inductively coupled plasma-mass spectrometry
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1008-1013.
|
[10] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[11] |
MENG kangkang, XIA Yukun.
Risks to safety of Ondansetron preparations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1034-1038.
|
[12] |
WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru.
Foreign methods for benefit-risk assessment of pharmaceutical products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.
|
[13] |
JIANG Hailun, ZHOU Xinbo, XIAO Dian, ZHONG Wu, LI Song.
Proteolysis targeting chimeric drugs and their potential risks
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 730-734.
|
[14] |
SHAO Bo, GUO Xiaoxin.
Review of pharmacovigilance of traditional Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 741-745.
|
[15] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|